Anais do 6º congresso da Sociedade Brasileira de Proteômica - Summit Brasileiro de Metabolômica
Áreas
Home
Áreas
Resumos para a área: PROTEÔMICA EM DOENÇAS CRÔNICAS
PEPGAT, A MULTIACTIVE SYNTHETIC CHITINASE-DERIVED PEPTIDE, ALTERS THE PROTEOMIC PROFILE AND REMODELS ONCOGENIC PATHWAYS IN COLORECTAL CANCER CELLS.
Gabriel Ferreira Barbosa (UFC - Universidade Federal do Ceará); Raquel Carvalho Montenegro (UFC - Universidade Federal do Ceará); Emerson Lucena da Silva (UFC - Universidade Federal do Ceará); Elmer Adilson Espino Zelaya (UFC - Universidade Federal do Ceará); Laís Lacerda Brasil-Oliveira (UFC - Universidade Federal do Ceará); Felipe Pantoja Mesquita (UFC - Universidade Federal do Ceará); Pedro Filho Noronha de Souza (UFC - Universidade Federal do Ceará);
Proteomic profiling revealed that synthetic peptide PepKAA affects key pathways in the development of colorectal cancer
Elmer Adilson Espino Zelaya (NPDM - Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará); Felipe Pantoja Mesquita (NPDM - Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará); Emerson Lucena da Silva (NPDM - Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará); Thiago Loreto Mathos (NPDM - Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará); Francisco Laio de Oliveira (NPDM - Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará); Raquel Carvalho Montenegro (NPDM - Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará); Pedro Filho Noronha de Souza (NPDM - Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará);
Área: Proteômica em doenças crônicas Palavras-chave: Differential proteomics; , Colorectal cancer;, Synthetic peptides; , Mass spectrometry.,
DIFFERENTIAL PROTEOMIC ANALYSIS REVEALS THAT THE ANTICANCER ACTION OF WIN55,212-2, CANNABINOID AGONIST, IS MEDIATED BY INHIBITION OF THE AKT/mTOR PATHWAY
Jonas Costa de França (LAFICA - Inflammation and Cancer Pharmacology Laboratory); Anamaria Falcão Pereira (LAFICA - Inflammation and Cancer Pharmacology Laboratory); Renata Rocha do Nascimento (LAFICA - Inflammation and Cancer Pharmacology Laboratory); Bianca de Souza Bezerra (LAFICA - Inflammation and Cancer Pharmacology Laboratory); Marcus Vinícius Saldanha Ribeiro (LAFICA - Inflammation and Cancer Pharmacology Laboratory); Daniel Castro Freire (LAFICA - Inflammation and Cancer Pharmacology Laboratory); Daiane Maria da Silva Brito (FARMAGEN - Pharmacogenetics Laboratory); Elmer Adilson Espino Zelaya (FARMAGEN - Pharmacogenetics Laboratory); Lais Lacerda Brasil de Oliveira (LOE - Experimental Oncology Laboratory); Carlos Roberto Koscky Paier (LOE - Experimental Oncology Laboratory); Pedro Filho Noronha de Souza (FARMAGEN - Pharmacogenetics Laboratory); Mariana Lima Vale (LAFICA - Inflammation and Cancer Pharmacology Laboratory);
